갑상선 결절의 분자생물학적 진단

키워드

참고문헌 (43)

1. [URL]
2. Cibas ES, "A prospective assessment defining the limitations of thyroid nodule pathologic evaluation", An Intern Med, 159(5), pp.325~332 (2013)
3. Bongiovanni M, "The Bethesda System for reporting thyroid cytopathology: a metaanalysis", Acta Cytol, 56(4), pp.333~339 (2012)
4. Cibas ES, "The Bethesda System for reporting thyroid cytopathology", Thyroid, 19(11), pp.1159~1165 (2009)
5. Yip L, "Clinical application of molecular testing of fineneedle aspiration specimens in thyroid nodules", Otolaryngol Clin North Am, 47(4), pp.557~571 (2014)
6. Ringel MD, "Overexpression and overactivation of Akt in thyroid carcinoma", Cancer Res, 61(16), pp.6105~6111 (2001)
7. Omur O, "An update on molecular biology of thyroid cancers", Crit Rev Oncol Hematol, 90(3), pp.233~252 (2014)
8. Pagan M, "The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes", BMC Bioinformatics, 17(Suppl 1), pp.6~ (2016)
9. Alexander EK, "Preoperative diagnosis of benign thyroid nodules with indeterminate cytology", New Engl J Med, 367(8), pp.705~715 (2012)
10. Alexander EK, "Multicenter clinical experience with the Afirma gene expression classifier", J Clin Endocrinol Metab, 99(1), pp.119~125 (2014)
11. McIver B, "An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules", J Clin Endocrinol Metab, 99(11), pp.4069~4077 (2014)
12. Marti JL, "Wide inter-institutional variation in performance of a molecular classifier for indeterminate thyroid nodules", Ann Surg Oncol, 22(12), pp.3996~4001 (2015)
13. Harrison G, "Evaluation of the Afirma gene expression classifier in repeat indeterminate thyroid nodules", Arch Pathol Lab Med, 141(7), pp.985~989 (2017)
14. Chaudhary S, "Impact of the Afirma gene expression classifier result on the surgical management of thyroid nodules with category III", IV cytology and its correlation with surgical outcome, 2016, pp.60(3), 205~210
15. Samulski TD, "Usage trends and performance characteristics of a "gene expression classifier" in the management of thyroid nodules: an institutional experience", Diagn Cytopathol, 44(11), pp.867~873 (2016)
16. Baca SC, "Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes", Cancer Cytopathol, 125(5), pp.313~322 (2017)
17. Hang JF, "The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier", Cancer Cytopathol, 125(9), pp.683~691 (2017)
18. Kloos RT, "A genomic alternative to identify medullary thyroid cancer preoperatively in thyroid nodules with indeterminate cytology", Thyroid, 26(6), pp.785~793 (2016)
19. Nikiforova MN, "Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules", Cancer, 124(8), pp.1682~1690 (2018)
20. Nikiforov YE, "Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm", suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay, 2014, pp.120(23), 3627~3634
21. Nikiforov YE, "Impact of the multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance", follicular lesion of undetermined significance cytology, 2015, pp.25(11), 1217~1223
22. Valderrabano P, "Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology", Endocr Relat Cancer, 24(3), pp.127~136 (2017)
23. Lithwick-Yanai G, "Multicentre validation of a microRNA-based assay for diagnosing indeterminate thyroid nodules utilising fine needle aspirate smears", J Clin Pathol, 70(6), pp.500~507 (2017)
24. Cantara S, "Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology", J Clin Endocrinol Metab, 95(3), pp.1365~1369 (2010)
25. Nikiforov YE, "Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples", J Clin Endocrinol Metab, 96(11), pp.3390~3397 (2011)
26. Labourier E, "Molecular testing for miRNA, mRNA, and DNA on fine-needle aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytology", J Clin Endocrinol Metab, 100(7), pp.2743~2750 (2015)
27. Wylie D, "Molecular classification of thyroid lesions by combined testing for miRNA gene expression and somatic gene alterations", J Pathol Clin Res, 2(2), pp.93~103 (2016)
28. Nikiforov YE, "Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors", JAMA Oncol, 2(8), pp.1023~1029 (2016)
29. Jiang XS, "Young investigator challenge: molecular testing in noninvasive follicular thyroid neoplasm with papillary-like nuclear features", Cancer Cytopathol, 124(12), pp.893~900 (2016)
30. Wong KS, "Noninvasive follicular variant of papillary thyroid carcinoma and the Afirma gene-expression classifier", Thyroid, 26(7), pp.911~915 (2016)
31. Ferris RL, "American Thyroid Association statement on surgical application of molecular profiling for thyroid nodules: current impact on perioperative decision making", Thyroid, 25(7), pp.760~768 (2015)
32. Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer", Thyroid, 26(1), pp.1~133 (2016)
33. "Thyroid carcinoma, version 1"[URL]
34. Xing M, "Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer", JAMA, 309(14), pp.1493~1501 (2013)
35. Prescott JD, "BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence", Surgery, 152(6), pp.984~990 (2012)
36. Xu B, "Primary thyroid carcinoma with low-risk histology and distant metastases: clinicopathologic and molecular characteristics", Thyroid, 27(5), pp.632~640 (2017)
37. Vuong HG, "A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma", Endocr Connect, 6(3), pp.R8~R17 (2017)
38. Teng L, "Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma", Oncotarget, 8(13), pp.22023~22033 (2017)
39. Moon S, "Effects of coexistent BRAFV600E and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: a metaanalysis", Thyroid, 27(5), pp.651~660 (2017)
40. Matsuse M, "TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors", Sci Rep, 7, pp.41752~ (2017)
41. Ibrahimpasic T, "Genomic alterations in fatal forms of non-anaplastic thyroid cancer: identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence", Clin Cancer Res, 23(19), pp.5970~5980 (2017)
42. Kim TH, "Refining dynamic risk stratification and prognostic groups for differentiated thyroid cancer with TERT promoter mutations", J Clin Endocrinol Metab, 102(5), pp.1757~1764 (2017)
43. Oishi N, "Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation", Mod Pathol, 30(11), pp.1527~1537 (2017)

관련 논문AI추천